Wall Street brokerages expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will post earnings per share (EPS) of ($0.37) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from ($0.43) to ($0.27). The business is expected to issue its next quarterly earnings results on Tuesday, February 6th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.22) per share for the current fiscal year, with EPS estimates ranging from ($2.72) to ($1.95). For the next year, analysts anticipate that the business will report earnings of ($1.80) per share, with EPS estimates ranging from ($2.10) to ($1.32). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.14).
Kala Pharmaceuticals (NASDAQ:KALA) opened at $13.61 on Tuesday. Kala Pharmaceuticals has a 52-week low of $11.81 and a 52-week high of $26.75. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14.
A number of large investors have recently bought and sold shares of the stock. Orbimed Advisors LLC bought a new stake in Kala Pharmaceuticals during the third quarter valued at $54,251,000. Caxton Corp bought a new stake in Kala Pharmaceuticals during the third quarter valued at $12,430,000. Victory Capital Management Inc. bought a new stake in Kala Pharmaceuticals during the third quarter valued at $12,414,000. OxFORD Asset Management LLP bought a new stake in Kala Pharmaceuticals during the third quarter valued at $4,374,000. Finally, JPMorgan Chase & Co. bought a new stake in Kala Pharmaceuticals during the third quarter valued at $4,037,000. 62.96% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/kala-pharmaceuticals-inc-kala-expected-to-announce-earnings-of-0-37-per-share/1820037.html.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.